MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Vical, Inc. (VICL) Announces Appointment Of Mammen P. Mammen, Jr., M.D., To Vice President Of Clinical Vaccines 0 comments
    Nov 2, 2012 6:06 PM | about stocks: VICL

    Vical Inc. announced today that Mammen P. "Anza" Mammen, Jr., M.D., has been appointed to the position of Vice President of Clincal Vaccines. Dr. Mammen is coming off of a 21-year career in the Army's Medical Corps, retiring as a colonel and recipient of the Legion of Merit. Throughout his career, Dr. Mammen has gained experience in the areas of clinical medicine, infectious disease research, medical diplomacy, clinical trials, vaccine program management, and public health.

    "Anza brings a wealth of infectious disease vaccine knowledge to Vical's management team, including extensive experience in infectious disease research and vaccine trials," said Vijay B. Samant, Vical's President and Chief Executive Officer. "His demonstrated expertise in clinical program management supplements Vical's existing strengths and provides focused support for our pipeline of vaccine development programs."

    In his most recent position, he worked as Infectious Disease Consultant and Chief, Pandemic Warning Team, U.S. Department of Defense, Fort Detrick, Maryland. From 2006 to 2010, he worked on vaccines in Advanced Development against dengue, hepatitis E, and HIV viruses as a Product Manager for the U.S. Army Medical Research and Material Command (USAMRMC), Fort Detrick, Maryland. While serving as Chief, Department of Virology, the Armed Forces Research Institute of Medical Sciences (AFRIMS), Thailand, from 2001 to 2006, Dr. Mammen contributed to a great array of the Army's U.S. Food and Drug Administration regulated vaccine studies. He also worked as the Principal Investigator of an infant trial to determine the safety and immunogenicity of the Army's live-attenuated dengue vaccine in Thailand, in collaboration with GlaxoSmithKline Biologicals (NYSE:GSK). This particular study was published in the American Journal of Tropical Medicine and Hygiene. Another position Dr. Mammen previously held was Project Director for an efficacy trial in Nepal of a recombinant hepatitis E vaccine, conducted in collaboration with GSK, published in The New England Journal of Medicine. Other previous assignments he has held include Infectious Disease Officer, Department of Virus Diseases, the Walter Reed Army Institute of Research (WRAIR), and Chief, Internal Medicine Clinic, 121st General Hospital, Seoul, South Korea.

    Dr. Mammen received his M.D. degree from the Pennsylvania State University College of Medicine and is Board-certified in Infectious Diseases. He has been elected as Fellow by the Infectious Disease Society of America (NASDAQ:IDSA) and the American College of Physicians (NYSE:ACP). He received his Internal Medicine and Infectious Disease clinical training from the Walter Reed Army Medical Center and audited the Medical Research Fellowship at WRAIR. He earned a B.A. degree in mathematics from Williams College. Dr. Mammen has authored or co-authored nearly 50 scientific publications spanning multiple emerging and re-emerging infectious diseases.

    For further information, please visit www.vical.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: VICL
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.